About this Journal Submit a Manuscript Table of Contents
ISRN Transplantation
Volume 2013 (2013), Article ID 683420, 15 pages
http://dx.doi.org/10.5402/2013/683420
Review Article

Posttransplant Lymphoproliferative Disorder after Cardiac Transplantation in Children: Life Threatening Complications Associated with Chemotherapy Combined with Rituximab

Department of Therapeutics Strategies for End Organ Dysfunction, Osaka University Graduate School of Medicine, Japan

Received 16 April 2013; Accepted 15 May 2013

Academic Editors: D. Caselli, H.-J. Kim, and C. Marchese

Copyright © 2013 Norihide Fukushima. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Kirk, A. I. Dipchand, L. B. Edwards, et al., “Registry of the The Registry of the International Society for Heart and Lung Transplantation: Fifteenth Pediatric Heart Transplantation Report-2012,” http://www.jhltonline.org/.
  2. J. Stehlik, L. B. Edwards, A. Y. Kucheryvaya, et al., “The Registry of the International Society for Heart and Lung Transplantation: 29th Official Adult Heart Transplant Report-2012,” The Journal of Heart and Lung Transplantation, vol. 31, no. 10, pp. 1052–1064, 2012. View at Publisher · View at Google Scholar
  3. G. Végso, M. Hajdu, and A. Sebestyén, “Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options,” Pathology and Oncology Research, vol. 17, no. 3, pp. 443–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Kollmar, S. Becker, M. K. Schilling, and C. A. Maurer, “Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy,” Transplantation, vol. 73, no. 4, pp. 669–670, 2002. View at Scopus
  5. J. C. Byrd, J. K. Waselenko, T. J. Maneatis et al., “Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance,” Journal of Clinical Oncology, vol. 17, no. 3, pp. 791–795, 1999. View at Scopus
  6. S.-J. Wu, W.-C. Chou, B.-S. Ko, and H.-F. Tien, “Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma,” Haematologica, vol. 92, no. 1, pp. 141–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. P. M. Millward, N. Bandarenko, P. P. Chang et al., “Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab,” Transfusion, vol. 45, no. 9, pp. 1481–1486, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. O. Armitage, “Staging non-Hodgkin lymphoma,” Ca-A Cancer Journal for Clinicians, vol. 55, no. 6, pp. 368–376, 2005. View at Scopus
  9. G. Opelz and B. Döhler, “Lymphomas after solid organ transplantation: a collaborative transplant study report,” American Journal of Transplantation, vol. 4, no. 2, pp. 222–230, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. L. Taylor, R. Marcus, and J. A. Bradley, “Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation,” Critical Reviews in Oncology/Hematology, vol. 56, no. 1, pp. 155–167, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. A. Webber, D. C. Naftel, F. J. Fricker et al., “Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study,” The Lancet, vol. 367, no. 9506, pp. 233–239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ross, P. Kouretas, P. Gamberg et al., “Ten- and 20-year survivors of pediatric orthotopic heart transplantation,” The Journal of Heart and Lung Transplantation, vol. 25, no. 3, pp. 261–270, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S.-Z. Gao, S. V. Chaparro, M. Perlroth et al., “Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-Year experience at Stanford University,” The Journal of Heart and Lung Transplantation, vol. 22, no. 5, pp. 505–514, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Chinnock, S. A. Webber, A. I. Dipchand, et al., “A 16-year multi-institutional study of the Role of age and EBV status on PTLD incidence among pediatric heart transplant recipients,” American Journal of Transplantation, vol. 12, pp. 3061–3068, 2012.
  15. C. Benden, L. B. Edwards, A. Y. Kucheryavaya, et al., “The Registry of the International Society for Heart and Lung Transplantation: Fifteenth Pediatric Lung and Heart-Lung Transplantation Report-2012,” The Journal of Heart and Lung Transplantation, vol. 31, no. 10, pp. 1087–1095, 2012.
  16. L. Tsao and E. D. Hsi, “The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders,” Archives of Pathology and Laboratory Medicine, vol. 131, no. 8, pp. 1209–1218, 2007. View at Scopus
  17. J. F. George, S. V. Pamboukian, J. A. Tallaj et al., “Balancing rejection and infection with respect to age, race, and gender: clues acquired from 17 years of cardiac transplantation data,” The Journal of Heart and Lung Transplantation, vol. 29, no. 9, pp. 966–972, 2010. View at Scopus
  18. N. A. Bakker, G. W. Van Imhoff, E. A. M. Verschuuren, and W. J. Van Son, “Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation,” Transplant International, vol. 20, no. 3, pp. 207–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. W. Loren, D. L. Porter, E. A. Stadtmauer, and D. E. Tsai, “Post-transplant lymphoproliferative disorder: a review,” Bone Marrow Transplantation, vol. 31, no. 3, pp. 145–155, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. F. George, D. O. Taylor, E. D. Blume et al., “Minimizing infection and rejection death: clues acquired from 19 years of multi-institutional cardiac transplantation data,” The Journal of Heart and Lung Transplantation, vol. 30, no. 2, pp. 151–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Kirk, L. B. Edwards, A. Y. Kucheryavaya et al., “The Registry of the International Society for Heart and Lung Transplantation: Thirteenth official pediatric heart transplantation report-2010,” The Journal of Heart and Lung Transplantation, vol. 29, no. 10, pp. 1119–1128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Benden, P. Aurora, M. Burch et al., “Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction,” The Journal of Heart and Lung Transplantation, vol. 24, no. 12, pp. 2103–2108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Schubert, C. Renner, M. Hammer et al., “Relationship of immunosuppression to Epstein–Barr viral load and lymphoproliferative disease in pediatric heart transplant patients,” The Journal of Heart and Lung Transplantation, vol. 27, no. 1, pp. 100–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Schubert, H. Abdul-Khaliq, H. B. Lehmkuhl et al., “Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients,” Pediatric Transplantation, vol. 13, no. 1, pp. 54–62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Green, M. G. Michaels, B. Z. Katz et al., “CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients,” American Journal of Transplantation, vol. 6, no. 8, pp. 1906–1912, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Green, J. Bueno, D. Rowe et al., “Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children,” Transplantation, vol. 70, no. 4, pp. 593–596, 2000. View at Scopus
  27. M. A. Bingler, B. Feingold, S. A. Miller et al., “Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children,” American Journal of Transplantation, vol. 8, no. 2, pp. 442–445, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Scheenstra, E. A. M. Verschuuren, A. De Haan et al., “The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients,” Transplant Infectious Disease, vol. 6, no. 1, pp. 15–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. D. A. Axelrod, R. Holmes, S. E. Thomas, and J. C. Magee, “Limitations of EBV-PCR monitoring to detect EBV associated post-transplant lymphoproliferative disorder,” Pediatric Transplantation, vol. 7, no. 3, pp. 223–227, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. L. J. Swinnen, M. R. Costanzo-Nordin, S. G. Fisher et al., “Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients,” New England Journal of Medicine, vol. 323, no. 25, pp. 1723–1728, 1990. View at Scopus
  31. J. D. Dayton, M. E. Richmond, R. G. Weintraub, A. T. Shipp, M. Orjuela, and L. J. Addonizio, “Role of immunosuppression regimen in post-transplant lymphoproliferative disorder in pediatric heart transplant patients,” The Journal of Heart and Lung Transplantation, vol. 30, no. 4, pp. 420–425, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. R. J. Gajarski, E. D. Blume, S. Urschel et al., “Infection and malignancy after pediatric heart transplantation: the role of induction therapy,” The Journal of Heart and Lung Transplantation, vol. 30, no. 3, pp. 299–308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Manlhiot, S. M. Pollock-BarZiv, C. Holmes et al., “Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients,” The Journal of Heart and Lung Transplantation, vol. 29, no. 6, pp. 648–657, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. K. L. Cox, L. S. Lawrence-Miyasaki, R. Garcia-Kennedy et al., “An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation,” Transplantation, vol. 59, no. 4, pp. 524–529, 1995. View at Scopus
  35. S. Cao, K. L. Cox, W. Berquist et al., “Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus,” Pediatric Transplantation, vol. 3, no. 1, pp. 22–26, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. B. S. Younes, S. V. McDiarmid, M. G. Martin et al., “The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric transplant patients,” Transplantation, vol. 70, no. 1, pp. 94–99, 2000. View at Scopus
  37. V. R. Dharnidharka, P.-L. Ho, D. M. Stablein, W. E. Harmon, and A. H. Tejani, “Mycophenolate, tacrolimus and posttransplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study,” Pediatric Transplantation, vol. 6, no. 5, pp. 396–399, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Caillard, V. Dharnidharka, L. Agodoa, E. Bohen, and K. Abbott, “Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression,” Transplantation, vol. 80, no. 9, pp. 1233–1243, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. B. D. Kahan, Y. K. Yakupoglu, L. Schoenberg et al., “Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients,” Transplantation, vol. 80, no. 6, pp. 749–758, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Majewski, M. Korecka, P. Kossev et al., “The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 8, pp. 4285–4290, 2000. View at Scopus
  41. M. Majewski, M. Korecka, J. Joergensen et al., “Immunosuppressive tor kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses,” Transplantation, vol. 75, no. 10, pp. 1710–1717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. M. A. Nalesnik, A. Zeevi, P. S. Randhawa et al., “Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders,” Clinical Transplantation, vol. 13, no. 1, pp. 39–44, 1999. View at Scopus
  43. N. Sculerati and M. Arriaga, “Otolaryngologic management of posttransplant lymphoproliferative disease in children,” Annals of Otology, Rhinology and Laryngology, vol. 99, no. 6, pp. 445–450, 1990. View at Scopus
  44. S. D. Zangwill, D. T. Hsu, M. R. Kichuk et al., “Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients,” The Journal of Heart and Lung Transplantation, vol. 17, no. 12, pp. 1161–1166, 1998. View at Scopus
  45. C. C. Tai, J. L. Curtis, J. R. Szmuszkovicz et al., “Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality,” Journal of Pediatric Surgery, vol. 43, no. 12, pp. 2174–2177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. T. G. Gross, J. C. Bucuvalas, J. R. Park et al., “Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation,” Journal of Clinical Oncology, vol. 23, no. 27, pp. 6481–6488, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. L. J. Addonizio and G. J. Boyle, “Posttransplant malignancy: risk, factors, incidence, diagnosis, treatment,” in Pediatric Heart Transplantation, C. E. Canter and J. K. Kirklin, Eds., vol. 2, Elsevier, Philadelphia, Pa, USA, 2007.
  48. K. Kawa, A. Sawada, M. Koyama, and M. Inoue, “Epstein-Barr virus infection after unrelated cord blood transplantation: reactivation or reinfection?” International Journal of Hematology, vol. 85, no. 3, pp. 267–269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Karras, E. Thervet, and C. Legendre, “Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature,” Transplantation, vol. 77, no. 2, pp. 238–243, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Awaya, A. Adachi, T. Mori et al., “Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma,” Leukemia Research, vol. 30, no. 8, pp. 1059–1062, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Chisuwa, Y. Hashikura, Y. Nakazawa et al., “Fatal hemophagocytic syndrome after living-related liver transplantation,” Transplantation, vol. 72, no. 11, pp. 1843–1846, 2001. View at Scopus
  52. M. Green, M. G. Michaels, S. A. Webber, D. Rowe, and J. Reyes, “The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients,” Pediatric Transplantation, vol. 3, no. 4, pp. 271–281, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. D. M. Walling, L. A. Andritsos, W. Etienne et al., “Molecular markers of clonality and identity in Epstein-Barr virus-associated B-cell lymphoproliferative disease,” Journal of Medical Virology, vol. 74, no. 1, pp. 94–101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. W. A. Mourad, A. Tulabah, A. Al Sayed et al., “The impact of the World Health Organization classification and clonality assessment of posttransplant lymphoproliferative disorders on disease management,” Archives of Pathology and Laboratory Medicine, vol. 130, no. 11, pp. 1649–1653, 2006. View at Scopus
  55. S. B. Murphy, “Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults,” Seminars in Oncology, vol. 7, no. 3, pp. 332–339, 1980. View at Scopus
  56. C. Divgi, “Imaging: staging and evaluation of lymphoma using nuclear medicine,” Seminars in Oncology, vol. 32, no. 1, pp. S11–S18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. V. Graute, N. Jansen, H. Sohn, et al., “Diagnostic role of whole-body 18F-FDG positron emission tomography in patients with symptoms suspicious for malignancy after heart transplantation,” The Journal of Heart and Lung Transplantation, vol. 31, pp. 958–966, 2012.
  58. C. von Falck, B. Maecker, E. Schirg et al., “Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring,” European Journal of Radiology, vol. 63, no. 3, pp. 427–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Bianchi, M. Pascual, M. Nicod, A. B. Delaloye, and M. A. Duchosal, “Clinical usefulness of FDG-PET/CT scan imaging in the management of posttransplant lymphoproliferative disease,” Transplantation, vol. 85, no. 5, pp. 707–712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. M.-K. Song, J.-S. Chung, H.-J. Shin et al., “Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement,” Annals of Hematology, vol. 91, pp. 697–703, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. D. E. Spratt, R. Diaz, J. McElmurray et al., “Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer,” Clinical Nuclear Medicine, vol. 35, no. 4, pp. 237–243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. T. H. La, E. J. Filion, B. B. Turnbull et al., “Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 5, pp. 1335–1341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. P. S. Randhawa, R. Jaffe, A. J. Demetris et al., “Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease,” New England Journal of Medicine, vol. 327, no. 24, pp. 1710–1714, 1992. View at Scopus
  64. H.-J. Delecluse, E. Kremmer, J.-P. Rouault, C. Cour, G. Bornkamm, and F. Berger, “The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders,” American Journal of Pathology, vol. 146, no. 5, pp. 1113–1120, 1995. View at Scopus
  65. R. Shaknovich, K. Basso, G. Bhagat et al., “Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling,” Haematologica, vol. 91, no. 10, pp. 1313–1320, 2006. View at Scopus
  66. N. L. Harris, E. S. Jaffe, J. Diebold et al., “The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997,” Histopathology, vol. 36, no. 1, pp. 69–87, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. N. L. Harris, S. H. Swerdlow, G. Frizzera, et al., “Posttransplant lymphoproliferative disorders,” in World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissue, E. S. Jaffe, N. L. Harris, H. Stein, and J. W. Vardiman, Eds., pp. 264–269, IARC Press, Lyon, France, 2001.
  68. S. H. Swerdlow, S. A. Webber, A. Chadburn, et al., “Posttransplant lymphoproliferative disorders (PTLD),” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, pp. 343–350, IARC Press, Lyon, France, 2008.
  69. K. Mucha, B. Foroncewicz, B. Ziarkiewicz-Wróblewska, M. Krawczyk, J. Lerut, and L. Pczek, “Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?” Nephrology Dialysis Transplantation, vol. 25, no. 7, pp. 2089–2098, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Parker, K. Bowles, J. A. Bradley et al., “Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients—BCSH and BTS Guidelines,” British Journal of Haematology, vol. 149, no. 5, pp. 675–692, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Hoshida, T. Li, Z. Dong, et al., “Lymphoproliferative disorders in renal transplant patients in Japan,” International Journal of Cancer, vol. 91, pp. 869–875, 2001.
  72. M. Benkerrou, A. Durandy, and A. Fischer, “Therapy for transplant-related lymphoproliferative diseases,” Hematology/Oncology Clinics of North America, vol. 7, no. 2, pp. 467–475, 1993. View at Scopus
  73. T. V. Cacciarelli, M. Green, R. Jaffe et al., “Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy,” Transplantation, vol. 66, no. 8, pp. 1047–1052, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. K. A. Newell, E. M. Alonso, P. F. Whitington et al., “Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infection and immunosuppression,” Transplantation, vol. 62, no. 3, pp. 370–375, 1996. View at Scopus
  75. M. M. Boucek, C. M. Mathis, M. S. Kanakriyeh, D. D. Hodgkin, R. J. Boucek Jr., and L. L. Bailey, “Serial echocardiographic evaluation of cardiac graft rejection after infant heart transplantation,” The Journal of Heart and Lung Transplantation, vol. 12, no. 5, pp. 824–831, 1993. View at Scopus
  76. R. R. Nepomuceno, C. E. Balatoni, Y. Natkunam, A. L. Snow, S. M. Krams, and O. M. Martinez, “Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas,” Cancer Research, vol. 63, no. 15, pp. 4472–4480, 2003. View at Scopus
  77. M. El-Salem, P. N. Raghunath, M. Marzec et al., “Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders,” Laboratory Investigation, vol. 87, no. 1, pp. 29–39, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Pascual, “Post-transplant lymphoproliferative disorder—the potential of proliferation signal inhibitors,” Nephrology Dialysis Transplantation, vol. 22, supplement 1, pp. i27–i35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. J. A. Sánchez-Brotons, J. M. Sobrino-Márquez, E. Lage-Gallé et al., “Preliminary experience with conversion from calcineurin inhibitors to everolimus in cardiac transplantation maintenance therapy,” Transplantation Proceedings, vol. 40, no. 9, pp. 3046–3048, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. A. O. Zuckermann and A. Z. Aliabadi, “Calcineurin-inhibitor minimization protocols in heart transplantation,” Transplant International, vol. 22, no. 1, pp. 78–89, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Jiménez-Rivera, Y. Avitzur, A. H. Fecteau, N. Jones, D. Grant, and V. L. Ng, “Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma,” Pediatric Transplantation, vol. 8, no. 3, pp. 243–248, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Kusuki, Y. Hashii, N. Fukushima et al., “Pediatric post-transplant diffuse large B cell lymphoma after cardiac transplantation,” International Journal of Hematology, vol. 89, no. 2, pp. 209–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Muti, S. Cantoni, P. Oreste et al., “Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment,” Haematologica, vol. 87, no. 1, pp. 67–77, 2002. View at Scopus
  84. R. L. Elstrom, C. Andreadis, N. A. Aqui et al., “Treatment of PTLD with rituximab or chemotherapy,” American Journal of Transplantation, vol. 6, no. 3, pp. 569–576, 2006. View at Publisher · View at Google Scholar · View at Scopus
  85. M. D. Pescovitz, “The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation,” Pediatric Transplantation, vol. 8, no. 1, pp. 9–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. V. Ganne, N. Siddiqi, B. Kamaplath et al., “Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder,” Clinical Transplantation, vol. 17, no. 5, pp. 417–422, 2003. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Choquet, V. Leblond, R. Herbrecht et al., “Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study,” Blood, vol. 107, no. 8, pp. 3053–3057, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. A. H. Blaes, B. A. Peterson, N. Bartlett, D. L. Dunn, and V. A. Morrison, “Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial,” Cancer, vol. 104, no. 8, pp. 1661–1667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. B. Coiffier, E. Lepage, J. Brière et al., “Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  90. N. Mounier, J. Briere, C. Gisselbrecht et al., “Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL),” Blood, vol. 101, no. 11, pp. 4279–4284, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. R. U. Trappe, S. Choquet, P. Reinke et al., “Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after upfront chemotherapy: the role of single-agent rituximab,” Transplantation, vol. 84, no. 12, pp. 1708–1712, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Fu, D. D. Weisenburger, W. W. L. Choi et al., “Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4587–4594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Orjuela, T. G. Gross, Y.-K. Cheung, B. Alobeid, E. Morris, and M. S. Cairo, “A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation,” Clinical Cancer Research, vol. 9, no. 10, pp. 3945S–3952S, 2003. View at Scopus
  94. C. Ara, S. Coban, C. Kayaalp, S. Yilmaz, and V. Kirimlioglu, “Spontaneous intestinal perforation due to non-Hodgkin's lymphoma: evaluation of eight cases,” Digestive Diseases and Sciences, vol. 52, no. 8, pp. 1752–1756, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Yokota, Y. Yamada, Y. Murakami et al., “Abdominal crisis caused by perforation of ileal lymphoma,” American Journal of Emergency Medicine, vol. 20, no. 2, pp. 136–137, 2002. View at Scopus
  96. D. Hoefer, H. Bonatti, G. Poelzl, W. Mark, H. Ott, and H. Antretter, “Cecal perforation as a rare initial manifestation of post-transplant lymphoproliferative disorder after cardiac transplantation,” The Journal of Heart and Lung Transplantation, vol. 24, no. 4, pp. 505–506, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. E. Kutsch, P. Kreiger, D. Consolini, and K. N. Furuya, “Colonic perforation after rituximab treatment for post-transplant lymphoproliferative disorder (PTLD),” Journal of Pediatric Gastroenterology and Nutrition, vol. 56, no. 6, p. e41, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Cornejo, M. Bohnenblust, C. Harris, and G. A. Abrahamian, “Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 4, pp. 857–860, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. Y.-C. Hsu, W.-C. Liao, H.-P. Wang, M. Yao, and J.-T. Lin, “Catastrophic gastrointestinal manifestations of post-transplant lymphoproliferative disorder,” Digestive and Liver Disease, vol. 41, no. 3, pp. 238–241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. “Rituximab: first report of intestinal perforations in an elderly patient: case report,” Reactions, vol. 1, no. 901, pp. 14–15, 2002.
  101. “Rituximab: gastrointestinal perforation,” Prescrire International, vol. 16, no. 91, p. 201, 2007.
  102. Health Canada, “Reports of bowel obstruction and gastrointestinal perforations with Rituxan,” Rituximab, November 2006, http://www.hc-sc.gc.ca/.
  103. J. J. Ifthikharuddin, L. A. Mieles, J. D. Rosenblatt, C. K. Ryan, and D. M. Sahasrabudhe, “CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab,” American Journal of Hematology, vol. 65, no. 2, pp. 171–173, 2000.
  104. V. Leblond, N. Dhedin, M.-F. M. Bruneel et al., “Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 772–778, 2001. View at Scopus
  105. A. D. Kirk, W. S. Cherikh, M. Ring et al., “Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab,” American Journal of Transplantation, vol. 7, no. 11, pp. 2619–2625, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. H. Khedmat and S. Taheri, “Heart allograft involvement by posttransplant lymphoproliferative disorders: report from the PTLD. Int survey,” Experimental and Clinical Transplantation, vol. 9, no. 4, pp. 258–264, 2011. View at Scopus
  107. M. D. Pescovitz, “The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation,” Pediatric Transplantation, vol. 8, no. 1, pp. 9–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. V. Ganne, N. Siddiqi, B. Kamaplath et al., “Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder,” Clinical Transplantation, vol. 17, no. 5, pp. 417–422, 2003. View at Publisher · View at Google Scholar · View at Scopus
  109. H. S. Kulkarni and P. M. Kasi, “Rituximab and cytokine release syndrome,” Case Reports in Oncology, vol. 5, pp. 134–140, 2012.
  110. G. Seifert, T. Reindl, S. Lobitz, K. Seeger, and G. Henze, “Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature,” Haematologica, vol. 91, no. 6, supplement, p. ECR23, 2006. View at Scopus
  111. J. C. Byrd, J. K. Waselenko, T. J. Maneatis et al., “Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance,” Journal of Clinical Oncology, vol. 17, no. 3, pp. 791–795, 1999. View at Scopus
  112. S.-J. Wu, W.-C. Chou, B.-S. Ko, and H.-F. Tien, “Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma,” Haematologica, vol. 92, no. 1, pp. 141–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. P. M. Millward, N. Bandarenko, P. P. Chang et al., “Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab,” Transfusion, vol. 45, no. 9, pp. 1481–1486, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Arai, A. Nogami, K. Imadome, et al., “Sequential monitoring of serum IL-6, TNF-a, and IFN-c levels in a CAEBV patient treated by plasma exchange and immunochemotherapy,” International Journal of Hematology, vol. 96, no. 5, pp. 669–673, 2012.
  115. P. Patel, V. Nandwani, J. Vanchiere, S. A. Conrad, and L. K. Scott, “Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A-An associated respiratory failure and hemodynamic shock,” Pediatric Critical Care Medicine, vol. 12, no. 2, pp. e87–e89, 2011. View at Publisher · View at Google Scholar · View at Scopus